Swing Trade Ideas

🏃🚀✅  WAI 4.37, UP 46% 🚀  from October

🏃🚀✅  ABVE 5.20, UP 215% 🚀  from October

🏃🚀✅  BITF 4.72, UP 263% 🚀  from October

🏃🚀✅  SCNX 1.61, UP 131% 🚀  from October

🏃🚀✅  NBY 1.34, UP 21% 🚀  from October

🏃🚀✅  SCNX high  1.38  97% 🚀  from October

🏃🚀✅  SOAR  high 4.42  227% 🚀  from Aug swing

🏃🚀✅  TBH  high 1.89  58% 🚀  from Aug swing

🏃🚀✅  BTBT  high 4.39  46% 🚀  from Aug swing

🏃🚀✅  SOAR  high 4.36  220% 🚀  from Aug swing

🏃🚀✅  PRSO  high  2   73  🚀  from Sep swing

🏃🚀✅  TBH  high  2.28 38  🚀  from Sep swing

🏃🚀✅ SABS high 2.63 25% 🚀  from Sep swing

🏃🚀✅ PLUG high 3.55 115% 🚀 

🏃🚀✅ ACRV high 1.90 19% 🚀 from Sep swing

🏃🚀✅ PRSO  high 1.27  10% 🚀 from Sep swing

 ✅ $CIGL potential entry: $2.55 – $2.65
🎯 PT1: $3.20 – $3.60 🎯 PT2: $3.70 – $4.30 🎯 PT3: $4.40 – $4.90
🚫 Stop: Below $2.30 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 CIGL potential swing 2.55/.65, stop if below 2.30 or daily max risk per trade @ recently acquired assets of Software Risk to boost facilities management capabilities, recent partnership with Ryde to open new  income streams for drivers in Singapore's growing security and facilities sectors , company provides security and safety solutions to commercial, financial, industrial and government clients, 

 ✅ $XTIA potential entry: $1.50 – $1.60
🎯 PT1: $1.80 – $2.40 🎯 PT2: $2.50 – $2.80 🎯 PT3: $2.90 – $3.30
🚫 Stop: Below $1.20 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 XTIA potential swing  11.40/.50, stop if below 1.20 or daily max risk per trade @ back to support from recent high above 2 on offering announcement, price at 1.60,  recent partnership announcement with Valkyrie to develop Vanguard platform, an intelligent technology system for the next generation of vertical takeoff and landing aircraft, recently selected Garmin G700 TXi Avionics for TriFan 600 xVTOL Aircraft, annual stockholders meeting 11/14/2025,  company is an aviation/air-mobility focused, Maxim group buy rating,  

 ✅ $SCNX potential entry: $0.70 – $0.75
🎯 PT1: $1.10 – $1.50 🎯 PT2: $1.60 – $2.20 🎯 PT3: $2.30 – $2.60
🚫 Stop: Below $0.60 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Another rinse and repeat from recent runner,   back to support from recent high above 2.60, recent offering at $1.20 /share, recently announced  the start of commerical sales for ARBLI, the first FDA-approved ready to use liquid losasrtan to tis distribution center, marking major commercialization milestones, Arbli is the first and only FDA-approved ready-to-use oral liquid losartan available in the United States, designed to treat hypertension in patients over six years old, reduce stroke risk in patients with hypertension and left ventricular hypertrophy, and treat diabetic nephropathy in certain patients with type 2 diabetes, does have active mixed shelf, be mindful on next spike, 

 ✅ $OPAD potential entry: $2.25 – $2.35
🎯 PT1: $2.80 – $3.20 🎯 PT2: $3.30 – $3.80 🎯 PT3: $3.90 – $4.60
🚫 Stop: Below $2.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 back to support from recent high near 5, recently secured $4.8M AI robot sales deal, recent reveres split, ultra small float, company offers corporate business training, consulting, advisory and transaction services in China 

 ✅ WAI entry: $3
🎯 PT1: $3.50 – $3.90 🎯 PT2: $4.00 – $4.50 🎯 PT3: $4.60 – $5.20
🚫 Stop: Below $2.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to support from recent high near 5, recently secured $4.8M AI robot sales deal, recent reveres split, ultra small float, company offers corporate business training, consulting, advisory and transaction services in China 

 ✅ $GNS potential entry: $0.70 – $0.80
🎯 PT1: $1.20 – $1.60 🎯 PT2: $1.70 – $2.20 🎯 PT3: $2.30 – $2.80
🚫 Stop: Below $0.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high near 5, recently secured $4.8M AI robot sales deal, recent reveres split, ultra small float, company offers corporate business training, consulting, advisory and transaction services in China 

 ✅ INEO entry: $0.82 – $0.85
🎯 PT1: $1.20 – $1.60 🎯 PT2: $1.70 – $2.30 🎯 PT3: $2.40 – $2.80
🚫 Stop: Below $0.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 recently awarded aa multi-million dollar contract from PSA Singapore, recently signed collaboration with HyCee to develop, deploy hydrogen-related technologies and infrastructure in Singapore , back to consolidation from recent high, company focuses on cloud-based IoT to retail analytics and advertising services targeting retailers and brands 

 ✅ CLRB entry: $3.40
🎯 PT1: $3.80 – $4.50 🎯 PT2: $4.60 – $5.00 🎯 PT3: $5.10 – $5.80
🚫 Stop: Below $3.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 near 52wk low , small float, recently received rare pediatric drug designation (RPDD) for iopofosine |131 in inoperable relapsed or refractory pediatric high-grade glioma, recently submitted CMA apllication for iopososine |131 expected early 2026, company focuses on developing targeted cancer therapies using proprietary Phospholipid drug conjugate (PDC) platform, pipeline include iopososine }131, aimed at delivering a radioactive isotope )iodine-131) directly into cancer cells, company also developing treatment for disease wigh high unmet need Roth Capital price target $18, 

 ✅ $PRSO potential entry: $1.35–$1.45

🎯 Potential PT1: $1.70 -2.30, 🎯 PT2: $2.40–$2.80, 🎯 PT3: $2.90–$3.50
🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Another rinse and repeat from recent runner,  previously secured $1.1M through inducement offer agreement, ,secured $0.9M order from FWA equipment supplier, partnered with WeLink to expand access to high-speed broadband across dense US metro areas, company focuses on fabless semiconductor/mmWave wireless technology, , Benchmark Co buy rating, price target $3, 

 ✅ STAK potential entry: $0.68–$0.73
🎯 PT1: $1.00–$1.40 🎯 PT2: $1.50–$2.20 🎯 PT3: $2.30–$2.80
🚫 Stop: Below $0.65 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recent IPO, back to near 52wk low from 52wk high above 4.50, company focused on research, development, manufacturing and sale of specialized oil-field production & maintenance equipment 

 ✅ $XTKG entry: $1.50 – $1.60
🎯 PT1: $2.00 – $2.40 🎯 PT2: $2.50 – $3.20 🎯 PT3: $3.30 – $3.80
🚫 Stop: Below $1.20 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup
recently acquired creation intelligent to boost gaming portfolio, company focuses on digital solutions and technology, operating across four primary segments: digital technologies, crypto mining, renewable energy, and Argi-tech, DOES have active mixed shelf, be mindful on next spike 

 ✅ $CMND potential entry: $0.90 – $0.95
🎯 PT1: $1.30 – $1.60 🎯 PT2: $1.70 – $2.30 🎯 PT3: $2.40 – $2.80
🚫 Stop: below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 near 52wk low, recently enrolled last patient for first cohort of CMND-100 trial for the treatment of AUD (alcohol use disorder) , recently filed and announced publication of US patent application on binge drinking addiction and compulsive behaviors, also blished international patent application for therapy targeting obesity and metabolic syndrome in collaboration with SciSparc, also recently secured IRB approval from Hadassah Medical Center for phase 1/2a trial of Novel AUD treatment, company focuses on the development of psychedelic-derived therapeutics for mental health, neurological disorders, lead candidate, CMND-100 for alcohol use disorder (AUD), does have mixed shelf, be mindful on next spike, 

 ✅ $DSS entry $1.20 – $1.30
🎯 PT1: $1.60 – $1.90 🎯 PT2: $2.00 – $2.50 🎯 PT3: $2.60 – $2.80
🚫 Stop: below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup
company focuses on health information software development and systems integration, providing services and solutions used daily by thousands of clinicians and administration staff nationwide in the public and private sectors, 

 ✅ $LEXX entry $0.80 – $0.90
🎯 PT1: $1.20 – $1.60 🎯 PT2: $1.70 – $2.30 🎯 PT3: $2.40 – $2.80
🚫 Stop: below $0.75 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high above 1.40,  recently expanded strategic outreach and secured new patents, recently awarded four new patents covering diabetes, elilepsy, antiviral treatments Does have mixed shelf, be mindful on next spike 

 ✅ $CSAI potential entry: $1.30 – $1.35
🎯 PT1: $1.55 – $1.90 🎯 PT2: $2.00 – $2.60 🎯 PT3: $2.70 – $3.30
🚫 Stop: Below $1.20 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
Another rinse and repeat,  back to near 52wk low, small float, recently announced up to $5M share-repurchase program to enhance shareholder value, announced contract to secure luxury high-rise in HOuston, announced partnerships with National Property management firm to enhance security with AI Surveillance Solutions, also, announced partnership with Crypto-mining company to cut AI operation costs using renewable energy data center in Montana, won "Project Management Solution of the year", upcoming catalyst: present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8–10, 2025, company specializing in cloud-based video surveillance, storage, analytics and monitoring solutions, offering leverage AI and computer vision to enhance security systems, Analyst price target $6, buy rating,  does have active mixed shelf, be mindful on next spike 

 ✅ $VTAK entry $2.55 – $2.65
🎯 PT1: $2.80 – $3.30 🎯 PT2: $3.50 – $3.80 🎯 PT3: $3.90 – $4.30
🚫 Stop: below $2.20 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to near 52wk low from recent high above 4.50, recent 1/19 reverse split, small float,  recently received Approval for LockeT in the United Kingdom, announced introduction of LockeT product line into Italy, company specializes in medical device based in US, two main products: VIVO system is a non-invasive, ED cardiac mapping system that integrates ECG and imaging data to help localize ventricular arrhythmia origins before procedures, the other is LockeT device, a suture retention tool designed to optimize vascular closure after percutaneous procedures, aiming to speed up hemostasis and patient recovery,   does have mixed shelf, 

 ✅ $LRE potential entry: $1.45 – $1.55
🎯 PT1: $1.80 – $2.40 🎯 PT2: $2.50 – $2.90 🎯 PT3: $3.00 – $3.60
🚫 Stop: Below $1.20 or 2 %– 5 % or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical setup
back to support from recent high above 3, recently proposed dividend of $0.07 per share, expanded operations with launch of "master lease business " and new hotel site in Toyko, announced, company develops and sells luxury residential properties in Japan, also operates hotels in Tokyo and leases apartment building units in Japan and Dallas, TX, 

 ✅ $ZONE entry: $1.15 – $1.20
🎯 PT1: $1.40 – $1.80 🎯 PT2: $1.90 – $2.50 🎯 PT3: $2.60 – $3.80
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical setup 

 recently secured multi-million dollar contract for logistics firm, also recently entered sales agreement with Curvature, completed acquisition of Sanzonate Europe, enhancing leadership position within the industry, awarded $475,000 GSA contract, launched product rollout at New York airport, company makes devices that infuse water with ozone (pure aqueous ozone) for chemical-free cleaning in commercial/industrial settings (airports, hotels, education), does have active mixed shelf, be mindful on next spike 

 ✅ $GNSS entry: $2.12 – $2.17
🎯 PT1: $2.40 – $2.80 🎯 PT2: $2.90 – $3.50 🎯 PT3: $3.60 – $3.90
🚫 Stop: Below $2.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 Back to support from recent high, recently received $9M order from teh US Army for its long range acoustic, also recently secured $1.7M follow-on LRAD order from southeast Asia military as part of multi-year program for long range communication device systems, company provides protective communications solutions, serving the federal, state/local government (SLED), enterprise critical infrastructure , globally in >100 countries and all 50 US states, Roth MKM buy rating, 

 ✅ $AZTR entry: $0.70 – $0.72
🎯 PT1: $0.90 – $1.30 🎯 PT2: $1.40 – $1.80 🎯 PT3: $1.90 – $2.40
🚫 Stop: Below $0.65 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to near 52wk low from recent high, announces positive preclinical results for ATR01 treatment for ichthyosis vulgaris, detailed data will be presented at the BIO Europe conference in Vienna Austria, company focuses on precision dermatology using engineered proteins and live biotherapeutic products to treat skin disease, November 3-5, Maxim price target $4 

 ✅ $AZTR entry: $0.70 – $0.72
🎯
back to near 52wk low from recent high, announces positive preclinical results for ATR01 treatment for ichthyosis vulgaris, detailed data will be presented at the BIO Europe conference in Vienna Austria, company focuses on precision dermatology using engineered proteins and live biotherapeutic products to treat skin disease, November 3-5, Maxim price target $4 

 ✅ $GNSS potential entry: $2.12 – $2.17
🎯 PT1: $2.40 – $2.80 🎯 PT2: $2.90 – $3.50 🎯 PT3: $3.60 – $3.90
🚫 Stop: Below $2 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 Back to support from recent high, recently received $9M order from teh US Army for its long range acoustic, also recently secured $1.7M follow-on LRAD order from southeast Asia military as part of multi-year program for long range communication device systems, company provides protective communications solutions, serving the federal, state/local government (SLED), enterprise critical infrastructure , globally in >100 countries and all 50 US states, Roth MKM buy rating, 

✅ $LAZR entry: $1.85 – $1.90
🎯 PT1: $2.20 – $2.50 🎯 PT2: $2.60 – $3.20 🎯 PT3: $3.30 – $3.70
🚫 Stop: Below $1.60 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup
back to near 52wk low from recent high, recently started shipping Fresh  near 52wk low from recent high , company develops LiDAR hardware and perception software for autonomous vehicles, MarketBeat consensus price target $8 

✅ $VRME entry: $1.05 – $1.10
🎯 PT1: $1.30 – $1.70 🎯 PT2: $1.80 – $2.40 🎯 PT3: $2.50 – $2.80
🚫 Stop: Below $0.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 back to key support from recent high, company operates in brand protection and precision logistics
 

✅ EDBL entry: $1.70–$1.80
🎯 PT1: $2.00–$2.50 🎯 PT2: $2.60–$2.90 🎯 PT3: $3.00–$3.60
🚫 Stop: Below $1.65 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
Another rinse and repeat, back to near 52wk low from recent high, recently started shipping Fresh Potted and cut herbs to $KR, also recently launched Kick Sports Nutrition Bundle at PriceSmart Warehouse Clubs, expanded USDA Organic offerings to Angelo Caputo's Fresh markets previously expanded Pickle Party line through new retail placements, small float, recently announced its Kick, sports nutrition won 2025 Mindful Award Sports Nutrition "Product of the Year", which launched on $AMZN , also announced expansion of retail footprint across Northeast, company focused on growing organic herbs, lettuces and plant-based protein products using innovative greenhouse, hydroponic and vertical farming methods,

 ⏳⏳ SMS swing alert: ✅ DSY potential entry: $0.70–$0.73
🎯 PT1: $1.00–$1.10 🎯 PT2: $1.20–$1.70 🎯 PT3: $1.80–$2.20
🚫 Stop: Below $0.65 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to 52 wk low on recent offering price $.62 per share from recent 52wk high above $7, company focuses on personal care & consumer goods, product lines include sanitary napkins, panty liners
 

 ✅ $HOTH potential entry: $1.45 – $1.50
🎯 Potential PT1: $1.80 – $2.20 🎯 PT2: $2.30 – $2.80 🎯 PT3: $2.90 – $3.40
🚫 Potential Stop: Below $1.20 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
Another rinse and repeat, back to consolidation from recent high, recently partnered and expanded its AI Initiative through $NVDA AI enterprise subscription license, previously entered joint venture with $SILO Pharma to commercialize VA-invented obesity Drug, expanded phase II clinical trial for HT-001, topical gel treating skin toxicities, across Europe in collaboration with ICON, recent data demonstrated significant reduction in tumor growth, announced patent to develop anti-obesity treatments with US Depart. Of Veterans Affairs, also previously purchased up to $1M of $BTC.X as treasury reverse asset, upcoming catalysts: 1) IND filing for HT-KIT, which recently announced positive data, suppressing tumor growth in preclinical models, expected to submit early 2026, 2) upcoming presentation to highlight advancements in clinical pipeline at the upcoming BIO -Europe 2025 conference, November 3-5 in Vienna, Austria D. Boral capital price target $5, HC Wainwright price target $4 

 ✅ SCNX potential entry: $0.70 – $0.73
🎯 PT1: $1.10 – $1.50 🎯 PT2: $1.60 – $2.20 🎯 PT3: $2.30 – $2.60
🚫 Stop: Below $0.65 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup  

 back to near 52wk low, recent offering at $1.20 /share, recently announced shipment of ARBLI, the first FDA-approved ready to use liquid losasrtan to tis distribution center, marking major commercialization milestones, Arbli is the first and only FDA-approved ready-to-use oral liquid losartan available in the United States, designed to treat hypertension in patients over six years old, reduce stroke risk in patients with hypertension and left ventricular hypertrophy, and treat diabetic nephropathy in certain patients with type 2 diabetes, does have active mixed shelf, be mindful on next spike
 

 ✅ $NBY potential entry: $1.05 – $1.10
🎯 Potential PT1: $1.30 – $1.85🎯 PT2: $2.00 – $2.60 🎯 PT3: $2.70 – $3.50
🚫 Potential Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
Another rinse and repeat,  back to support from recent high above 4 on special dividend declaration, company is a specialty pharma company, main focus is non-antibiotic anti-infective products, recent 13D filing shows David Lazar 19.99% stake in the company as of 8/19/2025, Zacks upgraded to buy rating, Does have active mixed shelf, be mindful of next spike, 

 ✅ $IINN potential entry: $1.05 – $1.15
🎯 Potential PT1: $1.40 – $1.80 🎯 PT2: $2.00 – $2.60 🎯 PT3: $2.70 – $3.30
🚫 Potential Stop: Below $0.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to consolidation from recent high, Recently announced achieving breakthrough with HYLA blood sensor with 97.35% accuracy in latest performance, paving way FDA submission, recently announced a U.SA top hospital expanded its use of the INSPIRA ART100 System to lung transplantation procedures, also previously secured US patent for ART500, aiming to dominate $20 billion market,  does have active mixed shelf, be mindful on next spike, company is a medical device/life support tech focused, Litchfield Hills price target $2, buy rating,
 

 ✅ GTBP potential entry: $0.60 – $0.65
✅ $TBH potential entry: $1.15 – $1.20
🎯 Potential PT1: $1.80 – $2.20, 🎯 PT2: $2.30 – $2.80, PT3: $3.00 – $3.50
🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
Back to support from recent high above 4, merging with House of Doge in a reverse takeover transaction, expected to complete early 2026,  recently announced $4M investment in CleanCore's $DOGE.X treasury model, recently launched secure digital assets platform for NIL initiative, recently featured on RedChip small stocks, big money show on Bloomberg TV, Zacks Small-cap research price target $4.40, company operates a Gen-Z focused esports and gaming platform 

 ✅ $ATER potential entry: $0.95 – $1.00
🎯 Potential PT1: $1.30 – $1.80, 🎯 PT2: $2.00 – $2.70 🎯 PT3: $2.80 – $3.40
🚫 Potential Stop: Below $0.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 small float, recently launched Squatty Potty wipes and PurSteam Steam Station Max and Mueller Living Cordless Portable Vaccuum Sealer at $WMT Nationwide, also launched multiple products on Bestbuy.com, , previously initiates $3m stock buyback plan, company is a technology-driven consumer products specializing in e-commerce brands across various categories, portfolio includes : Squatty Potty, HomeLabs, Mueller Living, PurSteam, Healing Solutions, Photo Paper Direct, which primarily sold through $AMZN $WMT $TGT and company's own direct-to-consumer websites.
 

 ✅ GTBP potential entry: $0.60 – $0.65
🎯 Potential PT1: $0.80 – $1.40 🎯 PT2: $1.50 – $2.20 🎯 PT3: $2.30 – $2.90
🚫 Potential Stop: Below $0.55 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
near 52wk low from recent high above 1.20, recently announced progresses phase 1 trial of lead drug candidate for blood cancers, Roth MKM buy rating, Analyst price target $11, recent sec filing shows Five Narrow Lane 9.99% stake, company is a clinical stage immuno-oncology, focuses on cancer therapy using natural killer cells and tumor cells to enhance cancer cell killing, does have mixed shelf, be mindful on next spike 

 ✅ $OFAL potential entry: $1.05 – $1.10
🎯 Potential PT1: $1.50 – $1.80 🎯 PT2: $1.90 – $2.50 🎯 PT3: $2.60 – $3.30
🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
Another rinse repeat,  recent IPO, back to near support, now accepting crypto payments for architectural, AI solutions, recently entered LOI with NExt Investments to establish joint venture to develop Next-Generation Senior Care facility, also recently launched digital asset strategy to enhance senior housing development, , does have active mixed shelf, be mindful on next spike, company focusing on architectural and design services, serving both commercial and residential, primarily in Hong Kong, 

 ✅ $IMUX potential entry: $0.85 – $0.90
🎯 Potential PT1: $1.10 – $1.50 🎯 PT2: $1.60 – $1.85 🎯 PT3: $2.00 – $2.60🚫 Potential Stop: Below $0.55 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 Back to near 52wk low from recent high, recently announced positive clinical data from phase 2 of vidofludimus calcium for multiple sclerosis, Executive chairman recently bought 20,000 shares, CEO and Director Daniel Vitt bought 15,000 shares, CFO  bought 45,000, D. Boral Capital price target $10, B. Riley Securities price target $6, HC Wainwright price target $10,  Chardan Capital $3,  Brookline raised price target to $22 from $19, Leerink Partners buy rating, William Blair buy rating , upcoming catalyst: 1) top line data phase 3 ENSURE trials end of 2026, company focuses on development of oral, small-molecule drugs aimed at treating chronic inflammatory and autoimmune disease 

 ✅ $BMGL potential entry: $1.40 – $1.50
🎯 Potential PT1: $1.80 – $2.40 🎯 PT2: $2.50 – $2.80 🎯 PT3: $2.90 – $3.50
🚫 Potential Stop: Below $1.20 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
Small float, recently entered to purchase up to 10,000 $BTC up to $1 B via stock deal, , recently announced its subsidiary has been awarded #375M contract to supply essential healthcare products in Asia-Pacific until 10/31/2029, previously announced to acquire Bethesda Medical, company specializing in medical services including orthopedic surgery, trauma and sports medicine, spine and neurosurgical procedures, minimally invasive techniques, diagnostic imaging, and rehab services. 

 ✅ $PRFX potential entry: $1.30 – $1.40
🎯 Potential PT1: $1.80 – $2.50 🎯 PT2: $2.60 – $2.90 🎯 PT3: $3.00 – $3.70
🚫 Potential Stop: Below $1.20 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 Back to consolidation near 52wk low, small float, its DeepSolar recently joined $NVDA Connect Program to enhance solar forecasting, recently entered cataract surgery market with LayerBio Investment, previously announced new clinical trial for breakthrough OcuRing-K Technology targeting post-cataract surgery pain management,  OcuRing-K, a non-opiate, non-steroidal postoperative NSAID, sustained-release drug delivery system aimed at managing pain and inflammation after surgery, also previously launched AI pilot with Econergy in Romania, does have mixed shelf, company focuses on reformulating established therapeutics for extended, localized pain relief, be mindful on next spike 

 ✅ $KIDZ potential entry: $1.00 – $1.05
🎯 Potential PT1: $1.30 – $1.50 🎯 PT2: $1.60 – $1.90 🎯 PT3: $2.00 – $2.70
🚫 Potential Stop: Below $0.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
Another rinse and repeat,  recently announced to begin accepting $SOL.X as payment method, also partnership with Lifespace for AI hiring in education, , launched its AL learning genome within a secure sandbox powered by $AMZN web services, previously announced $SOL.X holdings over $11M, also partnership announcement with Everstake to launch branded validator on Solana, previously announced $400M equity deal to back Solana-based treasury strategy, previously announced to hire 2500 US based teachers over next 12 to 24 months, company is an AI-powered education technology company based in New York, offering online live courses for k-12 students in US and internationally, does have mixed shelf, be mindful on next big spike 

 ✅ $APM potential entry: $2.00 – $2.05
🎯 Potential PT1: $2.40 – $2.80 🎯 PT2: $3.00 – $3.40 🎯 PT3: $3.60 – $3.90
🚫 Potential Stop: Below $1.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Another rinse and repeat from recent high above 4.45, recently announced NASDAQ compliance, recently announced merger with DiamiR Bioscience, aiming to advance brain health solutions, expected to close Q4 2025, company focuses on targeting disease with unmet medical needs in oncology and infectious diseases. 

 ✅ $XTKG potential entry: $1.65 – $1.70
🎯 Potential PT1: $2.00 – $2.40 🎯 PT2: $2.50 – $3.20 🎯 PT3: $3.30 – $3.80
🚫 Potential Stop: Below $1.50 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast-moving | Technical Setup
Recently acquired creation intelligent to boost gaming portfolio, company focuses on digital solutions and technology, operating across four primary segments: digital technologies, crypto mining, renewable energy, and Argi-tech, DOES have active mixed shelf, be mindful on next spike, upcoming catalyst: 1) data for phase 1 SENT-202 study in acute myeloid leukemia expected Q4 

✅ $STEC potential entry: $1.30 – $1.40
🎯 Potential PT1: $1.70 – $2.20 🎯 PT2: $2.30 – $2.70 🎯 PT3: $2.80 – $3.00
🚫 Potential Stop: Below $1.10 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast-moving | Technical Setupourcing and distributing Asian food, as well as supplying kitchen cabinets and other home improvement products  

 ✅ CAPS potential entry: $1.20 – $1.30
🎯 Potential PT1: $1.50 – $1.80, 🎯 PT2: $1.90 – $2.40, 🎯 PT3: $2.50 – $2.90
🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
Another rinse and repeat, recently completed acquisition of Caroline Stone, began integration and expanded southeast presence, previously secured $3m for strategic acquisition, company focuses on developing peptide-based therapies for cardiovascular conditions, company DOES have active mixed shelf recently filed, be mindful on next big spike

 ✅ $APDN potential entry: $4.00 – $4.05
🎯 Potential PT1: $4.20 – $4.80, 🎯 PT2: $5.05 – $5.50, 🎯 PT3: $5.70 – $6.20
🚫 Potential Stop: Below $3.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Another rinse and repeat,  back to key 1 support, small float, Nevada-based company specializing in sourcing and distributing Asian food, as well as supplying kitchen cabinets and other home improvement products  

 ✅ $SILO potential entry: $0.60 – $0.65
🎯 Potential PT1: $0.80 – $1.20, 🎯 PT2: $1.40 – $1.75, 🎯 PT3: $2.00 – $2.30
🚫 Potential Stop: Below $0.45 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
Another rinse and repeat from recent high above 1.30, back to key support, near 52wk low, recent offering price at .87/share closed, recently signed strategic agreement with Fireblocks to advance crypto treasury strategy acquisition and security, also recently announced initial investment in $ETH.X and $SOL.X , announced Japanese patent for PTSD drug expanding global IP portfolio, previously  launched cryptocurrency advisory board, recently acquired digital assets from MAVS holdings, have until 12/24/25 to regain Nasdaq compliance by bringing price above $1 for 10 consecutive days, recently partnered with $HOTH for obesity treatment, upcoming catalyst: 1) preclinical data on SPC-15, intranasal therapy (5-HT4 receptor agonist) aimed at PTSD and anxiety, leveraging a fast-acting nose-to-brain delivery mechanism in Q3, 

 ✅ $MWYN potential entry: $1.05 – $1.10
🎯 Potential PT1: $1.30 – $1.70, 🎯 PT2: $1.80 – $2.20, 🎯 PT3: $2.40 – $3.00
🚫 Potential Stop: Below $0.95 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Another rinse and repeat,  back to key 1 support, small float, Nevada-based company specializing in sourcing and distributing Asian food, as well as supplying kitchen cabinets and other home improvement products  

 ✅ $ZONE potential entry: $1.90 – $2.00
🎯 Potential PT1: $2.30 – $2.80, 🎯 PT2: $2.90 – $3.60, 🎯 PT3: $3.70 – $4.40
🚫 Potential Stop: Below $1.75 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
Another rinse and repeat, recently secured multi-million dollar contract for logistics firm, also recently entered sales agreement with Curvature, completed acquisition of Sanzonate Europe, enhancing leadership position within the industry, awarded $475,000 GSA contract, launched product rollout at New York airport, company makes devices that infuse water with ozone (pure aqueous ozone) for chemical-free cleaning in commercial/industrial settings (airports, hotels, education), does have active mixed shelf, be mindful on next spike 

 ✅ $WALD potential entry: $1.85 – $1.90
🎯 Potential PT1: $2.30 – $2.70, 🎯 PT2: $2.80 – $3.20, 🎯 PT3: $3.30 – $4.80
🚫 Potential Stop: Below $0.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 Recently received FDA approval for Obagi injectable hyaluronic acid gel, expanding U.S market reach alongside other important skin care in 2026, company focuses on beauty and wellness, skin care , Telsey Advisory price target $3,